Fraud

BMJ 1998;317:1590 ( 5 December )

Letters

Fraud

Fair and efficient system of investigating alleged misconduct can be devised

Pharmaceutical industry follows guidelines on conduct of research

In NHS appointments, research output should not be used as yardstick of ability

Validating research retrospectively is difficult

Some aspects do not fall within remit of bodies examining fraud

Fraud at conferences needs to be addressed

Fair and efficient system of investigating alleged misconduct can be devised

The first 150 words of the full text of this article appear below.

EDITOR $---$ Only one of the five papers on dealing with research misconduct in the United Kingdom (that by Riis) mentions the pharmaceuticalindustry and the national medicines regulatory agencies $---$ and onlyas an aside.¹ Licences for drugs are granted on studies conductedby pharmaceutical companies and assessed by the regulators, sofraud endangerssafety.

In the United Kingdom the pharmaceutical industry has been responsible for uncovering misconduct and fraud. The initial evidenceis usually obtained by the company's clinical research associateswho monitor the centres. Fraud can include falsification of data(even phantom patients) and the ethics reviewprocess.

A company loses on average about £650 000 ($1m) a day in delay in registering a new drug. In addition, conducting a trialto good clinical practice standards costs about £20 000 ($32 000)a patient. Thus if a 25-patient study has to be repeated and 100days are lost a company can . . . [Full text of this article]

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

Technorati What's this?

Relevant Articles

The need for a national body for research misconduct: Richard Smith
BMJ 1998 316: 1686-1687. [Extract] [Full Text]

Dealing with research misconduct in the United Kingdom • An American perspective on research integrity • Conduct unbecoming $---$ the MRC's approach • An editor's response to fraudsters • Deception: difficulties and initiatives • Honest advice from Denmark: Drummond Rennie, Imogen Evans, Michael J G Farthing, Cyril Chantler, Shireen Chantler, and Povl Riis
BMJ 1998 316: 1726-1733. [Extract] [Full Text] [PDF]

North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care
BMJ 1998 316: 1733. [Full Text]